Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Structural basis for endotoxin neutralization by the eosinophil cationic protein.

Pulido D, Garcia-Mayoral MF, Moussaoui M, Velázquez D, Torrent M, Bruix M, Boix E.

FEBS J. 2016 Nov;283(22):4176-4191. doi: 10.1111/febs.13915.

PMID:
27696685
2.

A Novel RNase 3/ECP Peptide for Pseudomonas aeruginosa Biofilm Eradication That Combines Antimicrobial, Lipopolysaccharide Binding, and Cell-Agglutinating Activities.

Pulido D, Prats-Ejarque G, Villalba C, Albacar M, González-López JJ, Torrent M, Moussaoui M, Boix E.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6313-25. doi: 10.1128/AAC.00830-16.

PMID:
27527084
3.

Exploring the mechanisms of action of human secretory RNase 3 and RNase 7 against Candida albicans.

Salazar VA, Arranz-Trullén J, Navarro S, Blanco JA, Sánchez D, Moussaoui M, Boix E.

Microbiologyopen. 2016 Oct;5(5):830-845. doi: 10.1002/mbo3.373.

4.

Insights into the Antimicrobial Mechanism of Action of Human RNase6: Structural Determinants for Bacterial Cell Agglutination and Membrane Permeation.

Pulido D, Arranz-Trullén J, Prats-Ejarque G, Velázquez D, Torrent M, Moussaoui M, Boix E.

Int J Mol Sci. 2016 Apr 13;17(4):552. doi: 10.3390/ijms17040552.

5.

The first crystal structure of human RNase 6 reveals a novel substrate-binding and cleavage site arrangement.

Prats-Ejarque G, Arranz-Trullén J, Blanco JA, Pulido D, Nogués MV, Moussaoui M, Boix E.

Biochem J. 2016 Jun 1;473(11):1523-36. doi: 10.1042/BCJ20160245.

6.

Triazole double-headed ribonucleosides as inhibitors of eosinophil derived neurotoxin.

Chatzileontiadou DS, Parmenopoulou V, Manta S, Kantsadi AL, Kylindri P, Griniezaki M, Kontopoulou F, Telopoulou A, Prokova H, Panagopoulos D, Boix E, Balatsos NA, Komiotis D, Leonidas DD.

Bioorg Chem. 2015 Dec;63:152-65. doi: 10.1016/j.bioorg.2015.10.007.

PMID:
26551065
7.

Protein post-translational modification in host defense: the antimicrobial mechanism of action of human eosinophil cationic protein native forms.

Salazar VA, Rubin J, Moussaoui M, Pulido D, Nogués MV, Venge P, Boix E.

FEBS J. 2014 Dec;281(24):5432-46. doi: 10.1111/febs.13082.

8.
9.

Ribonucleases as a host-defence family: evidence of evolutionarily conserved antimicrobial activity at the N-terminus.

Torrent M, Pulido D, Valle J, Nogués MV, Andreu D, Boix E.

Biochem J. 2013 Nov 15;456(1):99-108. doi: 10.1042/BJ20130123.

PMID:
23962023
10.

Two human host defense ribonucleases against mycobacteria, the eosinophil cationic protein (RNase 3) and RNase 7.

Pulido D, Torrent M, Andreu D, Nogués MV, Boix E.

Antimicrob Agents Chemother. 2013 Aug;57(8):3797-805. doi: 10.1128/AAC.00428-13.

11.

Nucleotide binding architecture for secreted cytotoxic endoribonucleases.

Boix E, Blanco JA, Nogués MV, Moussaoui M.

Biochimie. 2013 Jun;95(6):1087-97. doi: 10.1016/j.biochi.2012.12.015. Review.

PMID:
23274129
12.

Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation.

Torrent M, Pulido D, Nogués MV, Boix E.

PLoS Pathog. 2012;8(11):e1003005. doi: 10.1371/journal.ppat.1003005.

13.

Insights into the glycosaminoglycan-mediated cytotoxic mechanism of eosinophil cationic protein revealed by NMR.

García-Mayoral MF, Canales A, Díaz D, López-Prados J, Moussaoui M, de Paz JL, Angulo J, Nieto PM, Jiménez-Barbero J, Boix E, Bruix M.

ACS Chem Biol. 2013 Jan 18;8(1):144-51. doi: 10.1021/cb300386v.

PMID:
23025322
14.

Structural determinants of the eosinophil cationic protein antimicrobial activity.

Boix E, Salazar VA, Torrent M, Pulido D, Nogués MV, Moussaoui M.

Biol Chem. 2012 Aug;393(8):801-15. doi: 10.1515/hsz-2012-0160. Review.

PMID:
22944682
15.

The "CPC clip motif": a conserved structural signature for heparin-binding proteins.

Torrent M, Nogués MV, Andreu D, Boix E.

PLoS One. 2012;7(8):e42692. doi: 10.1371/journal.pone.0042692.

16.

Discovering new in silico tools for antimicrobial peptide prediction.

Torrent M, Nogués MV, Boix E.

Curr Drug Targets. 2012 Aug;13(9):1148-57.

PMID:
22664076
17.

Editorial: novel strategies for the design of therapeutic antimicrobial peptides.

Boix E.

Curr Drug Targets. 2012 Aug;13(9):1119-20. No abstract available.

PMID:
22664070
18.

The sulfate-binding site structure of the human eosinophil cationic protein as revealed by a new crystal form.

Boix E, Pulido D, Moussaoui M, Nogués MV, Russi S.

J Struct Biol. 2012 Jul;179(1):1-9. doi: 10.1016/j.jsb.2012.04.023.

PMID:
22579681
19.

Lipopolysaccharide neutralization by antimicrobial peptides: a gambit in the innate host defense strategy.

Pulido D, Nogués MV, Boix E, Torrent M.

J Innate Immun. 2012;4(4):327-36. doi: 10.1159/000336713. Review.

20.

Antimicrobial action and cell agglutination by the eosinophil cationic protein are modulated by the cell wall lipopolysaccharide structure.

Pulido D, Moussaoui M, Andreu D, Nogués MV, Torrent M, Boix E.

Antimicrob Agents Chemother. 2012 May;56(5):2378-85. doi: 10.1128/AAC.06107-11.

Items per page

Supplemental Content

Loading ...
Support Center